Prospective Grant of Exclusive License: Method for the Diagnosis and Treatment of Vascular Disease, 36716 [E7-12898]
Download as PDF
<![CDATA[
36716
Federal Register / Vol. 72, No. 128 / Thursday, July 5, 2007 / Notices
National Institutes of Health Peer
Review Advisory Committee.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: National Institutes of
Health Peer Review Advisory Committee.
Date: August 27, 2007.
Time: 8:30 a.m. to 5 p.m.
Agenda: Provide technical and scientific
advice to the Director, National Institutes of
Health (NIH), the Deputy Director for
Extramural Research, NIH and the Director,
Center for Scientific Review (CSR), on
matters relating broadly to review and
procedures and policies for the evaluation of
scientific and technical merit of applications
for grants and awards.
Place: National Institutes of Health,
Natcher Building, 45 Center Drive, Rooms
E1–E2, Bethesda, MD 20892.
Contact Person: Cheryl A. Kitt, PhD,
Executive Secretary, Center for Scientific
Review, National Institutes of Health, 6701
Rockledge Drive, Room 3030, MSC 7776,
Bethesda, MD 20892, 301–435–1112.
kittc@csr.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. the statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted the stringent procedures for
entrance onto the NIH campus. All visitor
vehicles, including taxicabs, hotel, and
airport shuttles will be inspected before
being allowed on campus. Visitors will be
asked to show one form of identification (for
example, a government-issued photo ID,
driver’s license, or passport) and to state the
purpose of their visit.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: June 26, 2007.
Anna Snouffer,
Deputy Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–3246 Filed 7–3–07; 8:45 am]
sroberts on PROD1PC70 with NOTICES
BILLING CODE 4140–01–M
VerDate Aug<31>2005
18:43 Jul 03, 2007
Jkt 211001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Method for the Diagnosis and
Treatment of Vascular Disease
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services, is
contemplating the grant of an exclusive
license worldwide to Endothelix, Inc.,
having a place of business in Houston
TX, to practice the invention embodied
in HHS Ref. Nos. E–037–2003 and E–
125–2003, both entitled ‘‘Method for the
Diagnosis and Treatment of Vascular
Disease’’, corresponding to U.S. Patent
Application No. 60/426,545 filed
November 15, 2002, U.S. Patent
Application No. 60/445,417 filed
February 5, 2003, PCT Patent
Application PCT/US03/36317 filed
November 12, 2003, and U.S. Patent
Application No.10/534,626 filed May
11, 2005. The contemplated exclusive
license may be limited to the following
field of use: an FDA-approvable
vascular endothelial function diagnostic
test. The patent rights in this invention
have been assigned to the United States
of America.
DATES: Only written comments and/or
application for a license which are
received by the NIH Office of
Technology Transfer on or before
September 4, 2007 will be considered.
ADDRESSES: Requests for a copy of the
patent, inquiries, comments, and other
materials relating to the contemplated
license should be directed to: Tara L.
Kirby, PhD, Technology Licensing
Specialist, Office of Technology
Transfer, National Institutes of Health,
6011 Executive Boulevard, Suite 325,
Rockville, MD 20852–3804; Telephone:
301–435–4426; Facsimile: 301–402–
0220; E-mail: kirbyt@mail.nih.gov.
SUPPLEMENTARY INFORMATION:
Cardiovascular disease is a major health
risk throughout the industrialized
world. Atherosclerosis, the most
prevalent of cardiovascular diseases, is
the primary cause of heart attack, stroke,
and gangrene of the extremities. It is
also the principal cause of death in the
United States.
The inventors have developed a
technique for evaluating vascular
function by counting endothelial
progenitor cells (EPCs) in a blood
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
sample. They found that decreased
numbers of EPCs correlate significantly
with decreased vascular function. A
diagnostic test developed utilizing this
discovery would have the advantages of
being minimally invasive and low cost
compared to other currently available
diagnostics.
The invention describes methods for
diagnosing decreased vascular function,
detecting increased cardiovascular risk,
and diagnosing atherosclerosis. Also
included are methods for assaying the
number of endothelial progenitor cells
and methods for treating a subject with
decreased vascular function by
administering a therapeutically effective
amount of endothelial progenitor cells.
The prospective exclusive license will
be royalty-bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless,
within 60 days from the date of this
published Notice, the NIH receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: June 26, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–12898 Filed 7–3–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: The Development of Human
Therapeutics for the Treatment of
Cancer
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
part 404.7(a)(1)(i), that the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
E:\FR\FM\05JYN1.SGM
05JYN1
]]>Agencies
[Federal Register Volume 72, Number 128 (Thursday, July 5, 2007)]
[Notices]
[Page 36716]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-12898]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Method for the Diagnosis
and Treatment of Vascular Disease
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
an exclusive license worldwide to Endothelix, Inc., having a place of
business in Houston TX, to practice the invention embodied in HHS Ref.
Nos. E-037-2003 and E-125-2003, both entitled ``Method for the
Diagnosis and Treatment of Vascular Disease'', corresponding to U.S.
Patent Application No. 60/426,545 filed November 15, 2002, U.S. Patent
Application No. 60/445,417 filed February 5, 2003, PCT Patent
Application PCT/US03/36317 filed November 12, 2003, and U.S. Patent
Application No.10/534,626 filed May 11, 2005. The contemplated
exclusive license may be limited to the following field of use: an FDA-
approvable vascular endothelial function diagnostic test. The patent
rights in this invention have been assigned to the United States of
America.
DATES: Only written comments and/or application for a license which are
received by the NIH Office of Technology Transfer on or before
September 4, 2007 will be considered.
ADDRESSES: Requests for a copy of the patent, inquiries, comments, and
other materials relating to the contemplated license should be directed
to: Tara L. Kirby, PhD, Technology Licensing Specialist, Office of
Technology Transfer, National Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: 301-435-
4426; Facsimile: 301-402-0220; E-mail: kirbyt@mail.nih.gov.
SUPPLEMENTARY INFORMATION: Cardiovascular disease is a major health
risk throughout the industrialized world. Atherosclerosis, the most
prevalent of cardiovascular diseases, is the primary cause of heart
attack, stroke, and gangrene of the extremities. It is also the
principal cause of death in the United States.
The inventors have developed a technique for evaluating vascular
function by counting endothelial progenitor cells (EPCs) in a blood
sample. They found that decreased numbers of EPCs correlate
significantly with decreased vascular function. A diagnostic test
developed utilizing this discovery would have the advantages of being
minimally invasive and low cost compared to other currently available
diagnostics.
The invention describes methods for diagnosing decreased vascular
function, detecting increased cardiovascular risk, and diagnosing
atherosclerosis. Also included are methods for assaying the number of
endothelial progenitor cells and methods for treating a subject with
decreased vascular function by administering a therapeutically
effective amount of endothelial progenitor cells.
The prospective exclusive license will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless, within 60 days
from the date of this published Notice, the NIH receives written
evidence and argument that establishes that the grant of the license
would not be consistent with the requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Comments and objections submitted in response to
this notice will not be made available for public inspection, and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: June 26, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E7-12898 Filed 7-3-07; 8:45 am]
BILLING CODE 4140-01-P
